ADARx Pharmaceuticals, Inc.
corporate_fare Company Profile
ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 6 items for ADRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-01, rated 7/10. Across its 6 most recent items scored 7 or higher, the top rating is 8/10, with 2 rated 8 or above. Recent SEC coverage for ADRX spans 4, 8-K, 424B4.
Recent high-impact activity:
- ADARx Fully Exercises Underwriters' Option, IPO Proceeds Reach $513M
- OrbiMed Buys $16.15M in ADARx IPO, Converts 23.3M Preferred Shares
- Director George Simeon Buys $27.2M of ADARx Stock at IPO Price
- ADARx Closes $446M IPO and $89M AbbVie Private Placement
- ADARx Prices Upsized $446M IPO at $17/Share with AbbVie $89M Private Placement
Short Interest & Short Volume
On October 2, 2026, 61.4% of ADRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ADRX, detected from its recent SEC filings · based on capital-structure filings through 2026-09-26.
Upsized IPO Priced at $17.00/Share · AbbVie Concurrent Private Placement
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →